2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Great Hall AD
Access, Representation, Population Health, Treatment Considerations, Biological Therapies, Transfusion, Non-Biological Therapies, Palliative Care, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

324 Persistent racial/ethnic disparities in pediatric AML survival despite comparable end-of-induction response

Daniel J. Zheng, MD, MHS, MSHP, Gary Hettinger, PhD2, Quynh Long Khuong, MD, MS3, Catherine Aftandilian, MD4, Kira Bona, MD, MPH5, Alexis Chen Boulter, MD6, Emi Caywood, MD7, Caitlin W. Elgarten, MD, MSCE8, Cody Gathers, MD, MSHP9, Taumoha Ghosh, MD,MS10, Maria Monica Gramatges, MD, PhD11, Meret Henry, MD, MS12, Yuan-Shung V. Huang, MS13, Yimei Li, PhD14, Kelly Maloney, MD15, Amir Mian, MD, MBA16, Tamara P. Miller, MD, MSCE17, Rajen Mody, MBBS18, Regina M. Myers, MD19, Haley Newman, MD, MSCE20, Jose Luis Ortiz Jr, BA21, Alix E. Seif, MD, MPH22, Caroline Smith, MD23, Jamie Stokke, MD, MACM24, Smitha Hosahalli Vasanna, MD25, Xin Wang, MD, MSCE26, Naomi J. Winick, MD27, Jennifer Wilkes, MD, MSCE28, Victor Wong, MD29, Brian T. Fisher, DO, MSCE, MPH30, Richard Aplenc I, MD, PhD31, Kelly Diringer Getz, PhD, MPH32
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 New York University Grossman School of Medicine, New York City, New York, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Stanford University, Stanford, California, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Nemour's Children's Health, Wilmington, Delaware, United States, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
10 Primary Children's Hospital, Salt Lake City, Utah, United States, University of Utah, Salt Lake City, Utah, United States
11 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
12 Children's Hospital of Michigan, Detroit, Michigan, United States
13 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
14 University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 Children's Hospital of Colorado, Aurora, Colorado, United States, University Colorado School of Medicine, Aurora, Colorado, United States
16 Dell Children's Hospital, University of Texas, Austin, Texas, United States
17 Children’s Healthcare of Atlanta, Atlanta, Georgia, United States, Emory University, Atlanta, Georgia, United States
18 University of Michigan, Ann Arbor, Michigan, United States
19 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
20 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
21 University of Pennsylvania, Philadelphia, Pennsylvania, United States
22 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
23 University of Texas Southwestern Medical Center, Dallas, Texas, United States
24 Children's Hospital Los Angeles, Los Angeles, California, United States
25 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 University of Texas Southwestern Medical Center, Dallas, Texas, United States
28 Seattle Children's Hospital, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
29 Rady Children's Hospital-San Diego, San Diego, California, United States
30 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
31 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
32 University of Pennsylvania, Philadelphia, Pennsylvania, United States

Introduction: Non-Hispanic Black (NHB) and Hispanic children with acute myeloid leukemia (AML) experience worse overall survival (OS) compared to their non-Hispanic White (NHW) peers. Factors mediating these outcome disparities need to be identified to inform targeted and effective intervention. Our prior work has demonstrated that these survival disparities are not explained by differential cytomolecular risk, severe frontline organ toxicity, dexrazoxane utilization, or relapse rates. One of the strongest predictors of OS and risk stratification in pediatric AML is end of Induction I measurable residual disease (EOI1 MRD). However, EOI1 MRD’s role in outcome disparities is unknown. In a large, multi-institutional real-world cohort of children with AML, we assessed the association of EOI1 MRD with overall survival (OS) and event-free survival (EFS) by race/ethnicity.

Methods: This was a retrospective cohort analysis of patients in the REAL-AML cohort, a multi-institutional real-world cohort including pediatric (<19 years old) patients treated for de novo AML at 14 US institutions from 2011-2025. Patients with acute promyelocytic leukemia and Down syndrome were excluded due to differences in treatment paradigms and prognoses. Kaplan Meier survival curves were generated for OS (time elapsed between date of diagnosis and death from any cause) and EFS (time elapsed between date of diagnosis and the earliest event, i.e. relapse, refractory disease defined as ≥5% leukemic blasts in the bone marrow or peripheral blood or persistent extramedullary disease at the end of two induction cycles, or death). Patients were censored at loss to follow-up with a maximum follow-up time of five years. We used Cox models to compute hazard ratios and corresponding 95% confidence intervals, adjusting for a priori determined biologic factors of age, sex, and cytomolecular risk profile. In the primary analysis, we defined MRD positivity as ≥0.1% given that this was the cutoff historically used in the earlier years of the cohort. In a sensitivity analysis, we evaluated whether results differed when leveraging a more contemporary 0.05% cut-off among the subset of patients with data granular enough to use this definition.

Results: A total of 1021 patients (12.4% NHB, 26.8% Hispanic, median follow-up time of 4.6 years) were included in the analytic cohort. In the overall cohort, the 5-year OS and EFS were 68.1% (95% confidence interval [CI]: 65.0-71.2) and 52.7% (95% CI: 49.6, 56.1), respectively. The overall rate of EOI1 MRD positivity was 31.8%. EOI1 MRD positivity was associated with inferior OS (unadjusted HR 3.18, 95% CI: 2.54-4.01, p<0.001) and EFS (unadjusted HR 2.29, 95% CI: 1.77-2.97, p<0.001). NHB patients experienced inferior OS compared to NHW patients (hazards ratio [HR] 1.56, 95% CI: 1.11-2.20, p=0.01). Hispanic patients similarly trended towards worse OS (HR 1.26, 95% CI: 0.95-1.66, p=0.10) compared to NHW patients. However, the rates of EOI MRD positivity were comparable by race/ethnicity (NHB 30.7% vs. Hispanic 29.2% vs. NHW 31.6%, p=0.30). Multivariable adjusted models similarly did not demonstrate statistically significant associations between race/ethnicity and EOI MRD positivity (NHB HR 0.96, 95% CI: 0.69-1.24, p=0.80; Hispanic HR 0.96, 95% CI: 0.75-1.17, p=0.69; NHW as reference). Similar results were observed in a sensitivity analysis examining the contemporary positive MRD cut-off of 0.05% among the subset (N=519) with available data.

Conclusion: MRD is arguably the strongest prognostic biomarker in pediatric AML. Despite marked survival disparities, induction I response is comparable across racial/ethnic groups, arguing that treatment resistance does not drive these differential outcomes. Instead, further attention should be focused on post-remission care and downstream mechanisms (e.g. differential toxicity, salvage regimen selection at relapse, access to transplant, non-relapse mortality). An expanded analysis will evaluate response after Induction II (EOI2) and examine whether and how outcomes among those with positive EOI1 and EOI2 MRD differ by race/ethnicity.
Daniel J. Zheng, MD, MHS, MSHP: No relevant conflicts of interest to declare.